Wall Street Journal

    ViSci, a wholly owned subsidiary of BioLight, has filed an investigational new drug application to the U.S. FDA to initiate a phase 1/2a study of a subconjunctival latanoprost controlled-release insert for glaucoma.

    If approved, the three-month, multicenter study will test the safety and efficacy of different doses of the insert in 68 glaucoma patients. ViSci recently completed an ocular toxicology and safety study in animals.